RT @Osteoporosis_NL: Efcacy and safety of biosimilar denosumab (Arylia) compared to Prolia® in 190 postmenopausal osteoporosis: phase III,…
97 followers
77 followers
RT @Osteoporosis_NL: Efcacy and safety of biosimilar denosumab (Arylia) compared to Prolia® in 190 postmenopausal osteoporosis: phase III,…
3,313 followers
Efcacy and safety of biosimilar denosumab (Arylia) compared to Prolia® in 190 postmenopausal osteoporosis: phase III, randomized, 2-armed, double-blind, parallel, active-controlled, and noninferiority CT. A Jamshidi et al. Arthritis Res Ther 2022 Jun 30 ht
3,313 followers
Efficacy and safety of the biosimilar denosumab candidate (Arylia) was noninferior to the reference product (Prolia®) after 18 months in PMP osteoporosis in phase III RCT. Jamshidi A et al. Arthritis Res Ther 30 June 2022 https://t.co/EOxcDkJox9